TrumpRx has spent six months promoting lower drug prices, but critics argue the harder problem is whether patients can actually reach the pharmacy counter.
Adam Colborn, vice president of government affairs at the Academy of Managed Care Pharmacy, says affordability and access are not the same thing, and the distinction matters enormously.
Colborn made the argument in the third and final installment of a video interview series with Pharmaceutical Commerce, drawing a firm line between reduced prices on paper and genuine patient access to medicines.
He contends that pharmacy participation gaps in TrumpRx can leave patients stranded, even when the headline savings figures appear attractive and the political messaging is strong.
In earlier parts of the interview series, Colborn walked through an AMCP member survey examining the platform, which revealed significant skepticism about whether TrumpRx consistently delivers the lowest available price.
Colborn described the current savings narrative around TrumpRx as “more messaging than true data,” a pointed assessment from one of the managed care sector’s leading policy voices.
He also placed TrumpRx within the broader landscape of drug price-comparison tools, including Mark Cuban Cost Plus Drugs, GoodRx, Amazon, and manufacturer-run direct-to-consumer programmes such as Lilly Direct.
Colborn argued that the wider trend toward drug price “shop-ability” across these platforms is actually the more significant development, rather than TrumpRx specifically standing out on its own merits.
A critical unresolved issue across all these platforms, he noted, is that none of them have clearly shown how purchases made through them interface with a patient’s existing insurance benefits.
FTC settlements have required pharmacy benefit managers to eventually count TrumpRx purchases toward patient deductibles, adding a layer of regulatory complexity that will shape how useful the platform becomes in practice.
Colborn said how that deductible-counting requirement gets implemented is worth watching closely, as the operational detail could determine whether TrumpRx translates into meaningful relief for patients.
The broader question hanging over TrumpRx is whether a platform built around price comparisons can solve structural access problems that have long challenged the American prescription drug market.
Until the gap between affordable pricing and reliable pharmacy access is closed, Colborn’s argument suggests that the platform’s true impact will remain difficult to measure or verify with confidence.